Linked Life Data

15621761

Source:http://linkedlifedata.com/resource/pubmed/id/15621761

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2004-12-28
pubmed:abstractText
The available information regarding relevant treatment approaches and outcome in Japanese myeloma patients has been fragmentary and clarification of the position is required. The Japan Myeloma Study Group collected data on 1,383 patients who had been diagnosed and treated during the 11 year period between 1990 and 2000 from 16 participating hospitals and 1 treatment group to investigate the status of the management of multiple myeloma across Japan. There were 724 (53%) male and 643 (47%) female patients with median age being 66-years-old. More than 60% of the patients were classified as having stage III disease. As initial therapy, 1,162 (84.4%) patients were treated with chemotherapy and the median survival was 3.1 years. High-dose therapy followed by stem cell transplantation (SCT) as part of first-line therapy was given in 113 (7.4%) patients with median survival being 4.4 years.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1042-8194
pubmed:author
pubmed:issnType
Print
pubmed:volume
45
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2465-9
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Management of patients with multiple myeloma in Japan: data of 1,383 patients from 16 hospitals and 1 treatment group.
pubmed:affiliation
Nagoya City Midori General Hospital, Japan. kshimizu@hosp.midori.nagoya.jp
pubmed:publicationType
Journal Article